WallStSmart

DoorDash, Inc. Class A Common Stock (DASH)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DoorDash, Inc. Class A Common Stock generates 357% more annual revenue ($14.72B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 6.3%. DASH appears more attractively valued with a PEG of 1.76. WST earns a higher WallStSmart Score of 67/100 (B-).

DASH

Hold

47

out of 100

Grade: D+

Growth: 7.3Profit: 5.5Value: 4.0Quality: 7.0
Piotroski: 5/9Altman Z: 1.94

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DASHUndervalued (+9.2%)

Margin of Safety

+9.2%

Fair Value

$193.25

Current Price

$163.93

$29.32 discount

UndervaluedFair: $193.25Overvalued
WSTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$185.95

Current Price

$325.92

$139.97 premium

UndervaluedFair: $185.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DASH2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
33.1%10/10

Revenue surging 33.1% year-over-year

Market CapQuality
$74.66B9/10

Large-cap with strong market position

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

DASH4 concerns · Avg: 3.3/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.944/10

Grey zone — moderate risk

Profit MarginProfitability
6.3%3/10

6.3% margin — thin

P/E RatioValuation
81.2x2/10

Premium valuation, high expectations priced in

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : DASH

The strongest argument for DASH centers on Revenue Growth, Market Cap. Revenue growth of 33.1% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : DASH

The primary concerns for DASH are PEG Ratio, Altman Z-Score, Profit Margin. A P/E of 81.2x leaves little room for execution misses.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

DASH profiles as a hypergrowth stock while WST is a growth play — different risk/reward profiles.

DASH carries more volatility with a beta of 1.87 — expect wider price swings.

DASH is growing revenue faster at 33.1% — sustainability is the question.

DASH generates stronger free cash flow (537M), providing more financial flexibility.

Bottom Line

WST scores higher overall (67/100 vs 47/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DoorDash, Inc. Class A Common Stock

CONSUMER CYCLICAL · INTERNET RETAIL · USA

DoorDash, Inc. operates a logistics platform that connects merchants, consumers, and merchants in the United States and internationally. The company is headquartered in San Francisco, California.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?